EGFR and neoplasm: Our pathway analyses of the tumor cells (T), in which the xmrk oncogene, an activated EGFR homolog (Gómez et al., 2001), was activated, and tumor-reverted cells (RFP+R), in which the oncogene was repressed, suggested some activated signaling in tumor cells, including death receptor signaling, ERK5 signaling, CXCR4 signaling, Ephrin receptor signaling and HGF signaling.